Literature DB >> 25561778

Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Sanja Stojsavljević1, Marija Gomerčić Palčić1, Lucija Virović Jukić1, Lea Smirčić Duvnjak1, Marko Duvnjak1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a condition in which excess fat accumulates in the liver of a patient with no history of alcohol abuse or other causes for secondary hepatic steatosis. The pathogenesis of NAFLD and nonalcoholic steatohepatitis (NASH) has not been fully elucidated. The "two-hit" hypothesis is probably a too simplified model to elaborate complex pathogenetic events occurring in patients with NASH. It should be better regarded as a multiple step process, with accumulation of liver fat being the first step, followed by the development of necroinflammation and fibrosis. Adipose tissue, which has emerged as an endocrine organ with a key role in energy homeostasis, is responsive to both central and peripheral metabolic signals and is itself capable of secreting a number of proteins. These adipocyte-specific or enriched proteins, termed adipokines, have been shown to have a variety of local, peripheral, and central effects. In the current review, we explore the role of adipocytokines and proinflammatory cytokines in the pathogenesis of NAFLD. We particularly focus on adiponectin, leptin and ghrelin, with a brief mention of resistin, visfatin and retinol-binding protein 4 among adipokines, and tumor necrosis factor-α, interleukin (IL)-6, IL-1, and briefly IL-18 among proinflammatory cytokines. We update their role in NAFLD, as elucidated in experimental models and clinical practice.

Entities:  

Keywords:  Adipokines; Adiponectin; Cytokines; Ghrelin; Interleukin-1; Interleukin-18; Interleukin-6; Leptin; Nonalcoholic fatty liver disease; Tumor necrosis factor-α

Mesh:

Substances:

Year:  2014        PMID: 25561778      PMCID: PMC4277948          DOI: 10.3748/wjg.v20.i48.18070

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  281 in total

1.  Different effects of adiponectin isoforms in human monocytic cells.

Authors:  Markus Neumeier; Johanna Weigert; Andreas Schäffler; Gabriele Wehrwein; Ulf Müller-Ladner; Jürgen Schölmerich; Christian Wrede; Christa Buechler
Journal:  J Leukoc Biol       Date:  2006-01-24       Impact factor: 4.962

2.  Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes.

Authors:  T Kanemaki; H Kitade; M Kaibori; K Sakitani; Y Hiramatsu; Y Kamiyama; S Ito; T Okumura
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

3.  Adiponectin gene variant interacts with fish oil supplementation to influence serum adiponectin in older individuals.

Authors:  Aseel Alsaleh; Daria Crepostnaia; Zoitsa Maniou; Fiona J Lewis; Wendy L Hall; Thomas A B Sanders; Sandra D O'Dell
Journal:  J Nutr       Date:  2013-05-08       Impact factor: 4.798

4.  Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects.

Authors:  Timothy E Graham; Qin Yang; Matthias Blüher; Ann Hammarstedt; Theodore P Ciaraldi; Robert R Henry; Christopher J Wason; Andreas Oberbach; Per-Anders Jansson; Ulf Smith; Barbara B Kahn
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

5.  NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis.

Authors:  Aileen Dela Peña; Isabelle Leclercq; Jacqueline Field; Jacob George; Brett Jones; Geoffrey Farrell
Journal:  Gastroenterology       Date:  2005-11       Impact factor: 22.682

6.  Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes.

Authors:  C Lagathu; L Yvan-Charvet; J-P Bastard; M Maachi; A Quignard-Boulangé; J Capeau; M Caron
Journal:  Diabetologia       Date:  2006-07-25       Impact factor: 10.122

7.  Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome.

Authors:  Rocco Barazzoni; Michela Zanetti; Clara Ferreira; Pierandrea Vinci; Alessia Pirulli; Mariapia Mucci; Franca Dore; Maurizio Fonda; Beniamino Ciocchi; Luigi Cattin; Gianfranco Guarnieri
Journal:  J Clin Endocrinol Metab       Date:  2007-07-24       Impact factor: 5.958

8.  Liver NF-kappaB and AP-1 DNA binding in obese patients.

Authors:  Luis A Videla; Gladys Tapia; Ramón Rodrigo; Paulina Pettinelli; Daniela Haim; Catherine Santibañez; A Verónica Araya; Gladys Smok; Attila Csendes; Luis Gutierrez; Jorge Rojas; Jaime Castillo; Owen Korn; Fernando Maluenda; Juan C Díaz; Guillermo Rencoret; Jaime Poniachik
Journal:  Obesity (Silver Spring)       Date:  2009-01-22       Impact factor: 5.002

9.  Relationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers.

Authors:  Imen Boumaiza; Asma Omezzine; Jihène Rejeb; Lamia Rebhi; Amani Ouedrani; Nabila Ben Rejeb; Naoufel Nabli; Ahmed Ben Abdelaziz; Ali Bouslama
Journal:  Genet Test Mol Biomarkers       Date:  2012-06-26

Review 10.  Molecular studies of leptin: implications for renal disease.

Authors:  P Stenvinkel; F Lönnqvist; M Schalling
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

View more
  89 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

2.  Association of Adiponectin gene polymorphisms and nonalcoholic fatty liver disease.

Authors:  Hong-Jue Li; Chang-Ping Li; Chao Zhang; Xiao-Lin Zhong; Lei Shi
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Authors:  J E Nelson; P Handa; B Aouizerat; L Wilson; L A Vemulakonda; M M Yeh; K V Kowdley
Journal:  Aliment Pharmacol Ther       Date:  2016-10-11       Impact factor: 8.171

4.  Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.

Authors:  Noha F Hassan; Somaia A Nada; Azza Hassan; Mona R El-Ansary; Muhammad Y Al-Shorbagy; Rania M Abdelsalam
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 5.  Herbal medicines and nonalcoholic fatty liver disease.

Authors:  Hong Yao; Yu-Jie Qiao; Ya-Li Zhao; Xu-Feng Tao; Li-Na Xu; Lian-Hong Yin; Yan Qi; Jin-Yong Peng
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

6.  Adipokine Levels Versus Hepatic Histopathology in Bariatric Surgery Patients.

Authors:  Rafael Bergesch D'Incao; Cristiane Valle Tovo; Vanessa Suñé Mattevi; Diego Olschowsky Borges; Jane Maria Ulbrich; Gabriela Perdomo Coral; Mauricio Jacques Ramos; Nelson Guardiola Meinhardt
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

Review 7.  NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?

Authors:  Subada Soti; Kathleen E Corey; Jordan E Lake; Kristine M Erlandson
Journal:  Curr HIV/AIDS Rep       Date:  2018-06       Impact factor: 5.071

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin/AMPK pathway.

Authors:  Zhongping Li; Jiaoya Xu; Peiyong Zheng; Lianjun Xing; Hongyi Shen; Lili Yang; Li Zhang; Guang Ji
Journal:  Int J Clin Exp Med       Date:  2015-10-15

Review 10.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.